Enlivex Therapeutics Ltd (ENLV) Stock Price, Quote & News

Company Profile

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 620 8072

Website: www.enlivex.com

Address:

14 Einstein Street, Ness Ziona, Israel

IN0V8 Aug. 3 at 4:05 PM

$ENLV H.C. Wainwright adjusts target price to $80 from $20 to reflect reverse stock split

2 · Reply

Zackpedia Jul. 31 at 7:32 PM

$ENLV Nice dip to 1.8, resistance at 2.3

0 · Reply

HimHit Jul. 31 at 6:37 PM

$EVH Ladies and Gentleman I’M IN like $LESL and $ENLV

0 · Reply

macroaxis Jul. 31 at 6:35 PM

$ENLV Enlivex Therapeutics options call open interest after weekly move https://www.macroaxis.com/stock-options/ENLV/Enlivex-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

waeng Jul. 31 at 6:20 PM

$ENLV Go

0 · Reply

Baurjan9999 Jul. 31 at 5:26 PM

$ENLV 300$ 🚀🚀🚀

0 · Reply

moneymarker20188 Jul. 31 at 3:48 PM

$ENLV $10

1 · Reply

bigsmallit Jul. 31 at 10:54 AM

$ENLV If it continues to fall today, I will start buying small lots at progressively lower prices. If it rebounds, I will decide on the next steps as the situation unfolds.

0 · Reply

nopennys Jul. 30 at 9:57 PM

$ENLV will follow DFNS More dilution Gradually falls to 0.3 or below Reverse split and reset Squeeze once and dilute

0 · Reply

anarquia99 Jul. 30 at 8:42 PM

$ENLV don’t waste your time here go to AMSS it’s time to go up I’m in since Monday

0 · Reply

Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright

Jul 30, 2026, 10:00 AM EDT - 4 days ago

Enlivex Transcript: Study update

Jul 30, 2026, 8:00 AM EDT - 4 days ago

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

Jul 29, 2026, 8:00 AM EDT - 5 days ago

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

2026-07-28T12:36:35.000Z - 6 days ago

Enlivex Therapeutics announces $400M private placement

Jul 28, 2026, 8:00 AM EDT - 6 days ago

Enlivex Announces $400,000,000 Private Placement

Jul 20, 2026, 8:00 AM EDT - 14 days ago

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

2026-07-13T12:26:09.000Z - 21 days ago

Enlivex Therapeutics receives RMAT designation for Allocetra from FDA

Jul 13, 2026, 8:00 AM EDT - 21 days ago

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

2026-07-08T23:50:17.000Z - 26 days ago

Enlivex Therapeutics trading halted, news pending

2026-07-07T12:36:17.000Z - 27 days ago

Enlivex Therapeutics announces 1-for-15 reverse split

Jul 7, 2026, 8:00 AM EDT - 27 days ago

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Jun 24, 2026, 9:00 AM EDT - 5 weeks ago

Enlivex Slides: Investor presentation

Jun 24, 2026, 8:00 AM EDT - 5 weeks ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Jun 22, 2026, 8:45 AM EDT - 6 weeks ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

2026-06-15T13:01:02.000Z - 7 weeks ago

Enlivex Therapeutics announces issuance of Australian patent

Jun 15, 2026, 8:00 AM EDT - 7 weeks ago

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Jun 15, 2026, 7:00 AM EDT - 7 weeks ago

Enlivex Slides: Investor presentation

Jun 2, 2026, 8:00 AM EDT - 2 months ago

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

May 28, 2026, 8:00 AM EDT - 2 months ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

2026-05-27T15:37:44.000Z - 2 months ago

Enlivex comments on $100M commitment to Rain’s prediction market

May 27, 2026, 8:00 AM EDT - 2 months ago

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

2026-05-18T12:17:18.000Z - 2 months ago

Enlivex Therapeutics doses first patient in Allocetra trial

May 18, 2026, 8:00 AM EDT - 2 months ago

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

May 15, 2026, 4:10 PM EDT - 2 months ago

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Apr 28, 2026, 8:30 AM EDT - 3 months ago

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Apr 23, 2026, 8:30 AM EDT - 3 months ago

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

2026-04-21T20:54:59.000Z - 3 months ago

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

2026-04-21T12:58:15.000Z - 3 months ago

Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra

Apr 21, 2026, 8:30 AM EDT - 3 months ago

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Enlivex Registration statement: Registration filing

Apr 8, 2026, 8:30 AM EDT - 4 months ago

Ondo Global Markets Tokenizes Enlivex's Ordinary Shares

2026-04-07T10:07:47.000Z - 4 months ago

Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright

Mar 26, 2026, 8:30 AM EDT - 4 months ago

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Mar 25, 2026, 9:00 AM EDT - 4 months ago

Enlivex Earnings Call Transcript: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 4 months ago

Enlivex Annual report: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 4 months ago

Enlivex Quarterly report: Q4 2025

Mar 25, 2026, 8:30 AM EDT - 4 months ago

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Mar 24, 2026, 8:30 AM EDT - 4 months ago

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Enlivex Slides: Investor presentation

2026-03-23T12:21:45.000Z - 4 months ago

Enlivex Therapeutics announces FDA clearance of Allocetra new drug application

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

2026-02-18T17:40:32.000Z - 5 months ago

Enlivex Therapeutics management to meet virtually with BTIG

2026-02-10T13:11:38.000Z - 6 months ago

Enlivex Therapeutics announces new listing of RAIN token on Kraken

Feb 10, 2026, 8:00 AM EST - 6 months ago

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

2026-01-26T13:11:08.000Z - 6 months ago

Enlivex Therapeutics announces listing of RAIN token on WhiteBIT

Jan 26, 2026, 8:00 AM EST - 6 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

2026-01-23T13:05:21.000Z - 6 months ago

Enlivex Therapeutics shares to trade exclusively on Nasdaq

Jan 23, 2026, 8:00 AM EST - 6 months ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

2026-01-12T11:10:08.000Z - 7 months ago

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

2026-01-07T13:28:01.000Z - 7 months ago

Enlivex says RAIN token listed on KuCoin crypto exchange

Dec 23, 2025, 7:00 AM EST - 7 months ago

Enlivex Registration statement: Registration Filing

Dec 4, 2025, 8:00 AM EST - 8 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Nov 24, 2025, 10:00 AM EST - 9 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 7:55 AM EST - 9 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 6:40 AM EST - 9 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nov 14, 2025, 4:00 PM EST - 9 months ago

Enlivex Quarterly report: Q3 2025

Oct 28, 2025, 8:15 AM EDT - 9 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Sep 29, 2025, 8:15 AM EDT - 11 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 11, 2025, 8:00 AM EDT - 11 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Aug 29, 2025, 4:00 PM EDT - 1 year ago

Enlivex Quarterly report: Q2 2025

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Enlivex Transcript: Status Update

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Enlivex Press release: Status Update

Aug 18, 2025, 7:45 AM EDT - 1 year ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Jul 28, 2025, 8:30 AM EDT - 1 year ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jun 10, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 3, 2025, 6:00 PM EDT - 1 year ago

Enlivex Slides: Company Presentation

May 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Earnings release: Q1 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 2, 2025, 8:00 AM EDT - 1 year ago

Enlivex Registration statement: Registration Filing

Apr 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Annual report: Q4 2024

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 6, 2025, 7:00 AM EST - 1 year ago

Enlivex Slides: Company Presentation

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

IN0V8 Aug. 3 at 4:05 PM

$ENLV H.C. Wainwright adjusts target price to $80 from $20 to reflect reverse stock split

2 · Reply

Zackpedia Jul. 31 at 7:32 PM

$ENLV Nice dip to 1.8, resistance at 2.3

0 · Reply

HimHit Jul. 31 at 6:37 PM

$EVH Ladies and Gentleman I’M IN like $LESL and $ENLV

0 · Reply

macroaxis Jul. 31 at 6:35 PM

$ENLV Enlivex Therapeutics options call open interest after weekly move https://www.macroaxis.com/stock-options/ENLV/Enlivex-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

waeng Jul. 31 at 6:20 PM

$ENLV Go

0 · Reply

Baurjan9999 Jul. 31 at 5:26 PM

$ENLV 300$ 🚀🚀🚀

0 · Reply

moneymarker20188 Jul. 31 at 3:48 PM

$ENLV $10

1 · Reply

bigsmallit Jul. 31 at 10:54 AM

$ENLV If it continues to fall today, I will start buying small lots at progressively lower prices. If it rebounds, I will decide on the next steps as the situation unfolds.

0 · Reply

nopennys Jul. 30 at 9:57 PM

$ENLV will follow DFNS More dilution Gradually falls to 0.3 or below Reverse split and reset Squeeze once and dilute

0 · Reply

anarquia99 Jul. 30 at 8:42 PM

$ENLV don’t waste your time here go to AMSS it’s time to go up I’m in since Monday

0 · Reply

bigsmallit Jul. 30 at 8:29 PM

$ENLV RSI 9,03 😳

0 · Reply

Pacho_Unlimited1 Jul. 30 at 8:08 PM

$ENLV Lesson 1 of communication: be transparent and clear. Shai was not clear about the 400M today. Result: trust is gone and the stock continues to drop. Shai has caused the stock unnecessary damage today.

1 · Reply

Rickster4retirement Jul. 30 at 6:34 PM

$ENLV Approaching same levels as it was before the 1-15 RS within only a week of trades, and nothing left of my investment except some worthless shares. How does the SEC allow this scam to continue?

0 · Reply

FST3 Jul. 30 at 6:25 PM

$ENLV - it's ironic that the short sellers are proving management right. The $400M looks like a smart play, and the right move. This company has a drug that the FDA is eager to support and yet short sellers target it....it's at the mercy regardless what they do until results and therefore future funding will cost a lot more than the $400M announced today.

0 · Reply

anarquia99 Jul. 30 at 6:04 PM

$ENLV I bought at 1.94 juts 45 shares for the bounce today before the market close

0 · Reply

anarquia99 Jul. 30 at 6:02 PM

$ENLV thats my prediction for this company

0 · Reply

anarquia99 Jul. 30 at 6:01 PM

$ENLV next week 1 dollar and the next week .50 cents and then .10 cents and disappear

0 · Reply

anarquia99 Jul. 30 at 5:34 PM

$ENLV 1.96 dammm

0 · Reply

Pacho_Unlimited1 Jul. 30 at 4:07 PM

$ENLV I'm reading nothing about the financing of the 400M in the conference call script, and how the transaction will be proceed (in USD or otherwise). To me that gives not a comfortable feeling of this transaction. If I missed anything, please advise. https://www.tradingview.com/symbols/NASDAQ-ENLV/documents/

2 · Reply

jacksonjohn750 Jul. 30 at 3:39 PM

$ENLV true?

0 · Reply

FST3 Jul. 30 at 3:16 PM

$ENLV - I do believe what they are trying to do is valid and it makes sense and there is no intention of fraud. The growth of Rain tokens is really only go to hit highs when they will truly need it. If you look at the people behind the Rain Foundation, it's guys who know the business, previous CEO of Bitcoin is on the board. The stock is trading just above cash value, and most long term investors will be holding onto the shares until at least Q2, 2027 as I've been saying all along. Time to step away from the daily stock watch.

1 · Reply

Ygershon Jul. 30 at 9:09 AM

$ENLV A major announcement is coming today! Fasten your seatbelts.

1 · Reply

Market Cap	239.76M
Revenue (ttm)	0.00
Net Income (ttm)	-15.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	855,299
Avg Vol	487,302
Day's Range	N/A - N/A
Shares Out	237.38M
Stochastic %K	21%
Beta	1.63
Analysts	Sell
Price Target	$13.00